anurajms/meta_analysis huggingface dataset:
MESH terms:
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Epilepsy, Absence [*drug therapy, prevention & control]; 3. Ethosuximide [adverse effects, *therapeutic use]; 4. Lamotrigine [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Seizures [prevention & control]; 7. Treatment Failure; 8. Valproic Acid [adverse effects, *therapeutic use];
MESH terms:
Antibiotic therapy versus no antibiotic therapy for children aged 2 to 59 months with WHO‐defined non‐severe pneumonia and wheeze
1. Amoxicillin [adverse effects, *therapeutic use]; 2. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 3. Drug Administration Schedule; 4. Placebos [therapeutic use]; 5. Pneumonia [*drug therapy]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. *Respiratory Sounds; 9. Treatment Outcome; 10. World Health Organization;
MESH terms:
Interventions for treating iron deficiency anaemia in inflammatory bowel disease
1. Anemia, Iron-Deficiency [complications, *therapy]; 2. Bias; 3. Colitis, Ulcerative [*complications]; 4. Crohn Disease [*complications]; 5. Disaccharides [administration & dosage, adverse effects]; 6. Erythropoietin [administration & dosage]; 7. Ferric Compounds [administration & dosage, adverse effects]; 8. Ferric Oxide, Saccharated [administration & dosage, adverse effects]; 9. Fumarates [administration & dosage, adverse effects]; 10. Hematinics [*administration & dosage, adverse effects]; 11. Iron Compounds [administration & dosage, adverse effects]; 12. Maltose [administration & dosage, adverse effects, analogs & derivatives]; 13. Placebos [administration & dosage]; 14. Pyrones [administration & dosage, adverse effects]; 15. Randomized Controlled Trials as Topic [statistics & numerical data];
MESH terms:
Indomethacin for symptomatic patent ductus arteriosus in preterm infants
1. Bias; 2. Bronchopulmonary Dysplasia [epidemiology]; 3. Cause of Death; 4. Cyclooxygenase Inhibitors [administration & dosage, adverse effects, *therapeutic use]; 5. Ductus Arteriosus, Patent [*drug therapy, mortality, surgery]; 6. Enterocolitis, Necrotizing [chemically induced]; 7. Gastrointestinal Hemorrhage [chemically induced]; 8. Incidence; 9. Indomethacin [administration & dosage, adverse effects, *therapeutic use]; 10. Infant, Low Birth Weight; 11. Infant, Premature; 12. Ligation [statistics & numerical data]; 13. Oxygen Inhalation Therapy [statistics & numerical data]; 14. Placebos [therapeutic use]; 15. Randomized Controlled Trials as Topic [statistics & numerical data];
MESH terms:
Early full enteral feeding for preterm or low birth weight infants
1. Body Weight; 2. Enteral Nutrition [adverse effects, *methods]; 3. Enterocolitis, Necrotizing [epidemiology, etiology]; 4. Fluid Therapy; 5. Infant Formula; 6. Infant, Premature [*growth & development]; 7. Infant, Very Low Birth Weight [*growth & development]; 8. Milk, Human; 9. Randomized Controlled Trials as Topic; 10. Weight Gain;
MESH terms:
Oral hygiene care for critically ill patients to prevent ventilator‐associated pneumonia
1. Chlorhexidine [therapeutic use]; 2. *Critical Illness; 3. Incidence; 4. Intensive Care Units [statistics & numerical data]; 5. Length of Stay; 6. Mouthwashes [therapeutic use]; 7. Oral Hygiene [*methods]; 8. Pneumonia, Ventilator-Associated [epidemiology, mortality, *prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Respiration, Artificial [*adverse effects, statistics & numerical data]; 11. Toothbrushing [instrumentation, methods];
MESH terms:
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
1. *Ambulatory Care; 2. Anticoagulants [adverse effects, *therapeutic use]; 3. Antineoplastic Agents [adverse effects]; 4. Antithrombins [therapeutic use]; 5. Bias; 6. Factor Xa Inhibitors [therapeutic use]; 7. Hemorrhage [chemically induced]; 8. Heparin [adverse effects, therapeutic use]; 9. Heparin, Low-Molecular-Weight [adverse effects, therapeutic use]; 10. Neoplasms [complications, *drug therapy]; 11. Primary Prevention [*methods]; 12. Pulmonary Embolism [etiology, prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Venous Thromboembolism [etiology, *prevention & control]; 15. Warfarin [adverse effects, therapeutic use];
MESH terms:
Respiratory muscle training for cystic fibrosis
1. Breathing Exercises [*methods]; 2. Cystic Fibrosis [*therapy]; 3. Forced Expiratory Flow Rates; 4. Inhalation [*physiology]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Respiratory Muscles [*physiology]; 8. Vital Capacity;
MESH terms:
Magnesium sulphate for treating acute bronchiolitis in children up to two years of age
1. Acute Disease; 2. Albuterol [therapeutic use]; 3. Bias; 4. Bronchiolitis [*drug therapy]; 5. Bronchodilator Agents [administration & dosage, *therapeutic use]; 6. Drug Therapy, Combination [methods]; 7. Epinephrine [therapeutic use]; 8. Length of Stay; 9. Magnesium Sulfate [administration & dosage, *therapeutic use]; 10. Patient Readmission [statistics & numerical data]; 11. Placebos [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Saline Solution [therapeutic use]; 14. Severity of Illness Index;
MESH terms:
Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age
1. Administration, Oral; 2. Body Height; 3. Confidence Intervals; 4. *Growth; 5. Growth Disorders [epidemiology]; 6. Hypercalcemia [etiology]; 7. Hypercalciuria [etiology]; 8. Micronutrients [administration & dosage]; 9. Placebos [administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Vitamin D [*administration & dosage, adverse effects]; 12. Vitamins [*administration & dosage, adverse effects];
MESH terms:
Vitamin D supplementation for term breastfed infants to prevent vitamin D deficiency and improve bone health
1. 25-Hydroxyvitamin D 2 [blood]; 2. Bone and Bones [*physiology]; 3. Bone Density; 4. *Breast Feeding; 5. Hypercalcemia [etiology]; 6. Lactation; 7. *Mothers; 8. Randomized Controlled Trials as Topic; 9. Rickets [blood]; 10. Term Birth; 11. Vitamin D [*administration & dosage, adverse effects]; 12. Vitamin D Deficiency [epidemiology, *prevention & control]; 13. Vitamins [*administration & dosage, adverse effects];
MESH terms:
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants
1. Anti-Inflammatory Agents, Non-Steroidal [adverse effects, *therapeutic use]; 2. Cause of Death; 3. Cerebral Intraventricular Hemorrhage [epidemiology]; 4. Chronic Disease; 5. Ductus Arteriosus, Patent [mortality, *therapy]; 6. Enterocolitis, Necrotizing [epidemiology]; 7. Hemodynamics; 8. Ibuprofen [adverse effects, therapeutic use]; 9. Indomethacin [adverse effects, therapeutic use]; 10. Infant, Premature; 11. Ligation [methods]; 12. Lung Diseases [epidemiology]; 13. Pneumothorax; 14. Randomized Controlled Trials as Topic; 15. Time Factors; 16. Time-to-Treatment; 17. *Watchful Waiting;
MESH terms:
N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure
1. Acetylcysteine [adverse effects, *therapeutic use]; 2. Bias; 3. Cause of Death; 4. Hepatic Encephalopathy; 5. Liver Failure, Acute [*drug therapy, mortality, surgery]; 6. Liver Transplantation [statistics & numerical data]; 7. Placebos [therapeutic use]; 8. Prognosis; 9. Randomized Controlled Trials as Topic;
MESH terms:
Interventions to increase patient and family involvement in escalation of care for acute life‐threatening illness in community health and hospital settings
1. Acute Disease [mortality, psychology, therapy]; 2. Anxiety [prevention & control]; 3. Communication; 4. Consumer Health Information [methods]; 5. Critical Illness [mortality, psychology, *therapy]; 6. Disease Progression; 7. *Emergency Treatment; 8. *Family; 9. Health Knowledge, Attitudes, Practice; 10. Negotiating [methods]; 11. *Patient Acceptance of Health Care; 12. Patient Education as Topic [methods]; 13. Patient Participation [*methods]; 14. *Patient Safety; 15. Randomized Controlled Trials as Topic; 16. Self Efficacy; 17. Symptom Assessment [methods];
MESH terms:
Probiotics for treating acute infectious diarrhoea
1. Acute Disease; 2. Bias; 3. Diarrhea [*therapy]; 4. Probiotics [*therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Pneumococcal conjugate vaccines for preventing acute otitis media in children
1. Acute Disease; 2. Age Factors; 3. Heptavalent Pneumococcal Conjugate Vaccine [adverse effects, therapeutic use]; 4. Otitis Media [microbiology, *prevention & control]; 5. Otitis Media with Effusion [drug therapy]; 6. *Pneumococcal Vaccines [adverse effects, therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Vaccines, Conjugate [adverse effects, therapeutic use];
MESH terms:
Individualized versus standard diet fortification for growth and development in preterm infants receiving human milk
1. Bias; 2. Blood Urea Nitrogen; 3. Body Height; 4. Bone Diseases, Metabolic [epidemiology]; 5. Child Development [*physiology]; 6. Confidence Intervals; 7. Enteral Nutrition; 8. Enterocolitis, Necrotizing [epidemiology]; 9. *Food, Fortified; 10. Head [anatomy & histology, growth & development]; 11. *Infant Formula; 12. Infant Nutritional Physiological Phenomena; 13. Infant, Premature [*growth & development]; 14. Infant, Very Low Birth Weight [*growth & development]; 15. *Milk, Human; 16. Randomized Controlled Trials as Topic; 17. Retinopathy of Prematurity [epidemiology]; 18. Weight Gain;
MESH terms:
Comparison of different protein concentrations of human milk fortifier for promoting growth and neurological development in preterm infants
1. Bias; 2. Body Height; 3. Child Development [*physiology]; 4. Confidence Intervals; 5. Head [growth & development]; 6. Infant Formula [*chemistry]; 7. Infant Mortality; 8. Infant, Premature [blood, *growth & development]; 9. Intensive Care Units, Neonatal; 10. Length of Stay; 11. Milk Proteins [*administration & dosage]; 12. Milk, Human [*chemistry]; 13. Randomized Controlled Trials as Topic; 14. Weight Gain;
MESH terms:
Mechanically assisted walking training for walking, participation, and quality of life in children with cerebral palsy
1. Bias; 2. Body Weight; 3. Cerebral Palsy [*rehabilitation]; 4. *Motor Activity; 5. Neurological Rehabilitation [methods]; 6. *Orthotic Devices; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Time Factors; 10. Walking [*education]; 11. Walking Speed;
MESH terms:
Cognitive behavioural therapy for anxiety disorders in children and adolescents
1. Anxiety Disorders [*therapy]; 2. Bias; 3. *Cognitive Behavioral Therapy; 4. Confidence Intervals; 5. Depression [therapy]; 6. Lost to Follow-Up; 7. Parents; 8. Randomized Controlled Trials as Topic; 9. Remission Induction; 10. Time Factors; 11. *Waiting Lists;
MESH terms:
Band ligation versus sclerotherapy for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. Chronic Disease; 2. Esophageal and Gastric Varices [*complications]; 3. Gastrointestinal Hemorrhage [*prevention & control]; 4. Hypertension, Portal [*complications]; 5. Ligation [*methods]; 6. Liver Diseases [*complications]; 7. *Portal Vein; 8. Primary Prevention [methods]; 9. *Sclerotherapy; 10. Venous Thrombosis [*therapy];
MESH terms:
Rufinamide add‐on therapy for drug‐resistant epilepsy
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Bias; 3. Drug Resistant Epilepsy [*drug therapy]; 4. Drug Therapy, Combination; 5. Randomized Controlled Trials as Topic; 6. Triazoles [adverse effects, *therapeutic use];
MESH terms:
Pharmacological treatment for continuous spike‐wave during slow wave sleep syndrome and Landau‐Kleffner Syndrome
1. Landau-Kleffner Syndrome [*drug therapy]; 2. Sleep, Slow-Wave [*drug effects]; 3. Syndrome;
MESH terms:
Pit and fissure sealants versus fluoride varnishes for preventing dental decay in the permanent teeth of children and adolescents
1. Bias; 2. Bicuspid; 3. Cariostatic Agents [*therapeutic use]; 4. Dental Caries [*prevention & control]; 5. Dentition, Permanent; 6. Fluorides, Topical [therapeutic use]; 7. Molar; 8. Pit and Fissure Sealants [*therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea
1. Apnea [therapy]; 2. Continuous Positive Airway Pressure; 3. Disorders of Excessive Somnolence [therapy]; 4. Exercise; 5. Isotonic Contraction; 6. Myofunctional Therapy [*methods]; 7. Oropharynx [physiology]; 8. Randomized Controlled Trials as Topic; 9. Sleep Apnea, Obstructive [*therapy]; 10. Snoring [therapy]; 11. Therapeutic Irrigation; 12. Waiting Lists;
MESH terms:
Specialised early intervention teams for recent‐onset psychosis
1. Bias; 2. Community Mental Health Services; 3. Early Medical Intervention [*methods]; 4. Hospitalization [statistics & numerical data]; 5. Psychotic Disorders [*therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Specialised early intervention teams (extended time) for recent‐onset psychosis
1. Affective Disorders, Psychotic [*therapy]; 2. Bias; 3. Community Mental Health Services; 4. Confidence Intervals; 5. Early Medical Intervention [*methods]; 6. Randomized Controlled Trials as Topic; 7. Remission Induction [methods]; 8. Schizophrenia [*therapy]; 9. Time Factors;
MESH terms:
Physical activity interventions for people with congenital heart disease
1. Bias; 2. *Breathing Exercises; 3. Cardiorespiratory Fitness [*physiology]; 4. Exercise [*physiology]; 5. Heart Defects, Congenital [*rehabilitation]; 6. Muscle Strength; 7. Oxygen Consumption [physiology]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy
1. Anticonvulsants [*therapeutic use]; 2. Bias; 3. Cost-Benefit Analysis; 4. Epilepsy [*drug therapy, psychology]; 5. Medication Adherence [*psychology]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Self Efficacy;
MESH terms:
Virtual reality distraction for acute pain in children
1. Acute Pain [diagnosis, *prevention & control]; 2. Attention; 3. Bias; 4. Pain Management [methods]; 5. Pain Measurement; 6. Pain Perception; 7. Pain, Procedural [diagnosis, *prevention & control]; 8. Randomized Controlled Trials as Topic; 9. *Virtual Reality;
MESH terms:
Drug treatments for managing cystic fibrosis‐related diabetes
1. Administration, Oral; 2. Bias; 3. Blood Glucose [analysis]; 4. Carbamates [administration & dosage]; 5. Cystic Fibrosis [blood, *complications]; 6. Diabetes Mellitus [blood, *drug therapy, etiology]; 7. Fasting [blood]; 8. Hyperglycemia [drug therapy]; 9. Hypoglycemic Agents [*administration & dosage]; 10. Insulin [*administration & dosage]; 11. Insulin Glargine [administration & dosage]; 12. Insulin, Isophane [administration & dosage]; 13. Piperidines [administration & dosage]; 14. Randomized Controlled Trials as Topic;
MESH terms:
Early versus delayed continuous positive airway pressure (CPAP) for respiratory distress in preterm infants
1. Bias; 2. Bronchopulmonary Dysplasia [epidemiology]; 3. Continuous Positive Airway Pressure [*methods]; 4. *Infant, Premature; 5. Intermittent Positive-Pressure Ventilation [statistics & numerical data]; 6. Pneumothorax [epidemiology]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Distress Syndrome, Newborn [mortality, *therapy];
MESH terms:
Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants
1. Bronchopulmonary Dysplasia [etiology]; 2. Continuous Positive Airway Pressure [adverse effects, *methods]; 3. Infant, Low Birth Weight; 4. *Infant, Premature; 5. Intermittent Positive-Pressure Ventilation [adverse effects]; 6. Outcome Assessment, Health Care; 7. Pneumothorax [etiology]; 8. Pulmonary Surfactants [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Respiratory Distress Syndrome, Newborn [mortality, *therapy]; 11. Respiratory Insufficiency [prevention & control]; 12. Selection Bias; 13. Treatment Failure;
MESH terms:
Interventions to reduce contaminated aerosols produced during dental procedures for preventing infectious diseases
1. Aerosols; 2. Air Filters; 3. *Air Microbiology; 4. Bacterial Infections [*prevention & control]; 5. Colony Count, Microbial [methods]; 6. Dentistry; 7. Disinfectants; 8. Infection Control, Dental [economics, instrumentation, *methods]; 9. Occupational Diseases [*prevention & control]; 10. Randomized Controlled Trials as Topic [statistics & numerical data]; 11. Rubber Dams; 12. Suction; 13. Virus Diseases [*prevention & control];
MESH terms:
Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass
1. Adrenal Cortex Hormones [adverse effects, *therapeutic use]; 2. Bias; 3. Cardiac Surgical Procedures [*methods, mortality]; 4. Cardiopulmonary Bypass [*adverse effects, mortality]; 5. Cause of Death; 6. Dexamethasone [therapeutic use]; 7. Heart-Lung Machine [adverse effects]; 8. Hospital Mortality; 9. Hydrocortisone [therapeutic use]; 10. Inflammation [etiology, *prevention & control]; 11. Intensive Care Units, Pediatric [statistics & numerical data]; 12. Length of Stay; 13. Methylprednisolone [therapeutic use]; 14. Randomized Controlled Trials as Topic; 15. Respiration, Artificial [statistics & numerical data];
MESH terms:
Household interventions for secondary prevention of domestic lead exposure in children
1. Bias; 2. Dust [analysis, *prevention & control]; 3. Environmental Exposure [*prevention & control]; 4. Environmental Restoration and Remediation [*methods]; 5. Floors and Floorcoverings; 6. Lead [blood]; 7. Lead Poisoning [*prevention & control]; 8. Paint [toxicity]; 9. Randomized Controlled Trials as Topic; 10. Secondary Prevention [*methods]; 11. Soil Pollutants;
MESH terms:
Branched‐chain amino acid supplementation for improving growth and development in term and preterm neonates
1. Amino Acids, Branched-Chain [*administration & dosage]; 2. Child Development [*drug effects]; 3. Infant, Newborn [*growth & development]; 4. Infant, Premature [growth & development];
MESH terms:
Pine bark (Pinus spp.) extract for treating chronic disorders
1. Antioxidants [*therapeutic use]; 2. Asthma [drug therapy]; 3. Attention Deficit Disorder with Hyperactivity [drug therapy]; 4. Bias; 5. Bone Diseases, Metabolic [drug therapy]; 6. Brain Injuries, Traumatic [drug therapy]; 7. Cardiovascular Diseases [drug therapy]; 8. Chronic Disease [*drug therapy]; 9. Diabetes Mellitus, Type 1 [drug therapy]; 10. Diabetes Mellitus, Type 2 [drug therapy]; 11. Erectile Dysfunction [drug therapy]; 12. Flavonoids [*therapeutic use]; 13. Hypertension [drug therapy]; 14. Osteoarthritis [drug therapy]; 15. Pinus; 16. Plant Bark [*chemistry]; 17. Plant Extracts [*therapeutic use]; 18. Randomized Controlled Trials as Topic; 19. Sexual Dysfunctions, Psychological [drug therapy]; 20. Venous Insufficiency [drug therapy];
MESH terms:
Protein supplementation of human milk for promoting growth in preterm infants
1. Bias; 2. Body Height; 3. *Dietary Proteins; 4. *Dietary Supplements; 5. Enterocolitis, Necrotizing [epidemiology]; 6. Head [growth & development]; 7. *Infant Nutritional Physiological Phenomena; 8. Infant, Premature [*growth & development]; 9. Length of Stay [statistics & numerical data]; 10. *Milk, Human [chemistry]; 11. Randomized Controlled Trials as Topic; 12. Weight Gain;
MESH terms:
Interventions for preventing ophthalmia neonatorum
1. Anti-Infective Agents [*administration & dosage]; 2. Bias; 3. Blindness [prevention & control]; 4. Erythromycin [administration & dosage]; 5. Ophthalmia Neonatorum [*prevention & control]; 6. Povidone-Iodine [administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Silver Nitrate [administration & dosage]; 9. Tetracycline [administration & dosage]; 10. Trachoma [prevention & control]; 11. Vision Disorders [prevention & control];
MESH terms:
Aural toilet (ear cleaning) for chronic suppurative otitis media
1. Anti-Bacterial Agents [therapeutic use]; 2. Bias; 3. Chronic Disease; 4. Ciprofloxacin [therapeutic use]; 5. *Hygiene; 6. Otitis Media, Suppurative [*therapy]; 7. Randomized Controlled Trials as Topic; 8. Suction [methods]; 9. Time Factors;
MESH terms:
Quarantine alone or in combination with other public health measures to control COVID‐19: a rapid review
1. Bias; 2. Coronavirus Infections [epidemiology, mortality, prevention & control]; 3. COVID-19 [epidemiology, mortality, *prevention & control]; 4. Incidence; 5. *Models, Theoretical; 6. Observational Studies as Topic; 7. *Pandemics; 8. Physical Distancing; 9. *Public Health; 10. *Quarantine; 11. SARS-CoV-2 [pathogenicity]; 12. Schools; 13. Severe Acute Respiratory Syndrome [epidemiology, mortality, prevention & control]; 14. Travel; 15. World Health Organization;
MESH terms:
Systemic treatments for eczema: a network meta‐analysis
1. Antibodies, Monoclonal [therapeutic use]; 2. Antibodies, Monoclonal, Humanized [therapeutic use]; 3. Dermatologic Agents [*therapeutic use]; 4. Eczema [*drug therapy]; 5. Immunosuppressive Agents [*therapeutic use]; 6. *Network Meta-Analysis; 7. Placebos [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Treatment Outcome; 10. Ustekinumab [therapeutic use];
MESH terms:
Carbohydrate supplementation of human milk to promote growth in preterm infants
1. Body Weight; 2. Dietary Carbohydrates [*administration & dosage]; 3. *Dietary Supplements; 4. Enterocolitis, Necrotizing [epidemiology]; 5. Food Intolerance [epidemiology]; 6. *Infant Nutritional Physiological Phenomena; 7. Infant, Premature [*growth & development]; 8. Length of Stay; 9. *Milk, Human [chemistry]; 10. Oligosaccharides [administration & dosage]; 11. *Prebiotics;
MESH terms:
Psychological and social interventions for the prevention of mental disorders in people living in low‐ and middle‐income countries affected by humanitarian crises
1. Age Factors; 2. Anxiety [diagnosis, epidemiology]; 3. Bias; 4. Depression [diagnosis, epidemiology]; 5. *Developing Countries [statistics & numerical data]; 6. Mental Disorders [etiology, *prevention & control]; 7. Patient Dropouts [statistics & numerical data]; 8. *Psychotherapy; 9. Randomized Controlled Trials as Topic; 10. Social Problems [*psychology]; 11. Stress Disorders, Post-Traumatic [diagnosis, epidemiology]; 12. *Stress, Physiological; 13. Stress, Psychological [*complications]; 14. Waiting Lists;
MESH terms:
Psychological treatments for people with epilepsy
1. Bias; 2. Energy Metabolism; 3. Epilepsy [*psychology, *therapy]; 4. Fatigue [therapy]; 5. Psychotherapy; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Vitamin E supplementation in people with cystic fibrosis
1. alpha-Tocopherol [administration & dosage]; 2. Bias; 3. Cystic Fibrosis [*blood]; 4. *Dietary Supplements; 5. Exocrine Pancreatic Insufficiency [complications]; 6. Placebos [administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Vitamin E [*administration & dosage, blood, chemistry]; 9. Vitamin E Deficiency [prevention & control]; 10. Vitamins [*administration & dosage, chemistry];
MESH terms:
Hydrosurgical debridement versus conventional surgical debridement for acute partial‐thickness burns
1. Bias; 2. Burns [pathology, *surgery]; 3. Debridement [*methods]; 4. Hydrotherapy [*methods]; 5. Operative Time; 6. Skin Transplantation; 7. Surgical Wound Infection [epidemiology, etiology]; 8. Therapeutic Irrigation [methods]; 9. Time Factors; 10. Wound Healing;
MESH terms:
Pharmacotherapy for hyperuricaemia in hypertensive patients
1. Allopurinol [*therapeutic use]; 2. Blood Pressure [drug effects]; 3. Hypertension [complications, *drug therapy]; 4. Hyperuricemia [complications, *drug therapy]; 5. Patient Dropouts [statistics & numerical data]; 6. Placebos [therapeutic use]; 7. Prehypertension [drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Uricosuric Agents [*therapeutic use];
MESH terms:
Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis
1. Administration, Oral; 2. Aminosalicylic Acids [*administration & dosage]; 3. Anti-Inflammatory Agents, Non-Steroidal [*administration & dosage, adverse effects]; 4. Bias; 5. Colitis, Ulcerative [*drug therapy, prevention & control]; 6. Drug Administration Schedule; 7. Maintenance Chemotherapy [*methods]; 8. Medication Adherence [statistics & numerical data]; 9. Mesalamine [*administration & dosage]; 10. Patient Dropouts [statistics & numerical data]; 11. Placebos [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Recurrence; 14. Remission Induction [methods]; 15. Sulfasalazine [administration & dosage, adverse effects];
MESH terms:
Surgical interventions for primary congenital glaucoma
1. Glaucoma [*congenital, drug therapy, *surgery]; 2. Glaucoma Drainage Implants [adverse effects]; 3. Hyphema [etiology]; 4. Intraocular Pressure; 5. Mitomycin [therapeutic use]; 6. Postoperative Complications; 7. Randomized Controlled Trials as Topic; 8. Sclera [surgery]; 9. Trabecular Meshwork [surgery]; 10. Trabeculectomy [adverse effects, methods]; 11. Treatment Outcome;
MESH terms:
Interventions for American cutaneous and mucocutaneous leishmaniasis
1. Administration, Oral; 2. Antiprotozoal Agents [administration & dosage, adverse effects]; 3. Azithromycin [administration & dosage, adverse effects]; 4. BCG Vaccine [therapeutic use]; 5. Hyperthermia, Induced; 6. Immunocompetence; 7. Injections, Intramuscular; 8. Injections, Intravenous; 9. Interferon-gamma [therapeutic use]; 10. Leishmaniasis Vaccines [therapeutic use]; 11. Leishmaniasis, Cutaneous [*therapy]; 12. Leishmaniasis, Mucocutaneous [therapy]; 13. Meglumine Antimoniate [administration & dosage, adverse effects]; 14. Pentoxifylline [administration & dosage, adverse effects]; 15. Phosphorylcholine [administration & dosage, adverse effects, analogs & derivatives]; 16. Randomized Controlled Trials as Topic;
MESH terms:
Fat supplementation of human milk for promoting growth in preterm infants
1. Dietary Fats [*administration & dosage]; 2. *Dietary Supplements; 3. *Infant Nutritional Physiological Phenomena; 4. Infant, Premature [*growth & development]; 5. *Milk, Human;
MESH terms:
Antibiotic therapy for pelvic inflammatory disease
1. Aminoglycosides [adverse effects, therapeutic use]; 2. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 3. Azithromycin [adverse effects, therapeutic use]; 4. Cephalosporins [adverse effects, therapeutic use]; 5. Clindamycin [adverse effects, therapeutic use]; 6. Doxycycline [adverse effects, therapeutic use]; 7. Drug Therapy, Combination; 8. Nitroimidazoles [adverse effects, therapeutic use]; 9. Pelvic Inflammatory Disease [*drug therapy, microbiology]; 10. Publication Bias; 11. Quinolones [adverse effects, therapeutic use]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants
1. Anti-Inflammatory Agents [therapeutic use]; 2. Fetal Blood [cytology]; 3. Hydrocortisone [therapeutic use]; 4. Hypothermia, Induced; 5. Hypoxia-Ischemia, Brain [complications, mortality, *therapy]; 6. *Stem Cell Transplantation;
MESH terms:
Intravenous immunoglobulin for presumed viral myocarditis in children and adults
1. Acute Disease; 2. Bias; 3. Immunoglobulins, Intravenous [*therapeutic use]; 4. Myocarditis [mortality, *therapy, virology]; 5. Progression-Free Survival; 6. Randomized Controlled Trials as Topic; 7. Stroke Volume [drug effects]; 8. Virus Diseases [mortality, *therapy];
MESH terms:
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax
1. Antimalarials [administration & dosage, adverse effects, *therapeutic use]; 2. Drug Administration Schedule; 3. Glucosephosphate Dehydrogenase; 4. Malaria, Vivax [*drug therapy, enzymology]; 5. Primaquine [administration & dosage, adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Secondary Prevention;
MESH terms:
Digital contact tracing technologies in epidemics: a rapid review
1. Botswana [epidemiology]; 2. Cohort Studies; 3. Contact Tracing [instrumentation, *methods]; 4. Coronavirus Infections [epidemiology]; 5. COVID-19 [epidemiology, prevention & control]; 6. Disease Outbreaks [*prevention & control]; 7. Hemorrhagic Fever, Ebola [epidemiology, prevention & control]; 8. Mobile Applications [*statistics & numerical data]; 9. Models, Theoretical; 10. Patient Isolation [statistics & numerical data]; 11. Privacy; 12. Quarantine [statistics & numerical data]; 13. Secondary Prevention [methods, statistics & numerical data]; 14. Sierra Leone [epidemiology]; 15. Tuberculosis [epidemiology, prevention & control]; 16. United States [epidemiology]; 17. Whooping Cough [epidemiology, prevention & control];
MESH terms:
Mobility management to prevent, reduce, or delay driving a car in teenagers
1. Automobile Driving [*education]; 2. Bias; 3. Controlled Before-After Studies; 4. Intention; 5. Licensure [statistics & numerical data]; 6. Randomized Controlled Trials as Topic; 7. *Transportation;
MESH terms:
Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome
1. Acne Vulgaris [drug therapy]; 2. Body Mass Index; 3. Cardiovascular Diseases [prevention & control]; 4. Contraceptives, Oral, Combined [adverse effects, *therapeutic use]; 5. Drug Therapy, Combination; 6. Endometrial Neoplasms [prevention & control]; 7. Hirsutism [*drug therapy]; 8. Hypoglycemic Agents [*therapeutic use]; 9. Menstruation Disturbances [*drug therapy]; 10. Metformin [adverse effects, *therapeutic use]; 11. Polycystic Ovary Syndrome [complications, *drug therapy]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Oral non‐steroidal anti‐inflammatory drugs versus other oral analgesic agents for acute soft tissue injury
1. Acetaminophen [administration & dosage, adverse effects]; 2. Acute Disease; 3. Administration, Oral; 4. Analgesics [*administration & dosage, adverse effects]; 5. Analgesics, Opioid [administration & dosage, adverse effects]; 6. Anti-Inflammatory Agents, Non-Steroidal [*administration & dosage, adverse effects]; 7. Bias; 8. Contusions [*drug therapy]; 9. Pain [drug therapy]; 10. Randomized Controlled Trials as Topic; 11. Soft Tissue Injuries [*drug therapy]; 12. Sprains and Strains [*drug therapy]; 13. Time-to-Treatment;
MESH terms:
Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis
1. Administration, Oral; 2. Anti-Inflammatory Agents, Non-Steroidal [*administration & dosage, adverse effects]; 3. Bias; 4. Colitis, Ulcerative [*drug therapy]; 5. Drug Administration Schedule; 6. Induction Chemotherapy [methods]; 7. Mesalamine [*administration & dosage, adverse effects]; 8. Patient Dropouts [statistics & numerical data]; 9. Placebos [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Remission Induction; 12. Sulfasalazine [*administration & dosage, adverse effects]; 13. Treatment Failure;
MESH terms:
Pancreatic enzyme replacement therapy for people with cystic fibrosis
1. Abdominal Pain [epidemiology]; 2. Age Factors; 3. Capsules [administration & dosage]; 4. Cystic Fibrosis [*therapy]; 5. Delayed-Action Preparations; 6. Enzyme Replacement Therapy [adverse effects, *standards]; 7. Gastrointestinal Agents [therapeutic use]; 8. Microspheres; 9. Nutritional Status; 10. Pancreas [enzymology]; 11. Randomized Controlled Trials as Topic; 12. Weight Gain;
MESH terms:
Perioperative antibiotics for preventing post‐surgical site infections in solid organ transplant recipients
1. Anti-Bacterial Agents [*therapeutic use]; 2. *Antibiotic Prophylaxis; 3. Bias; 4. Graft Survival; 5. Pneumonia [epidemiology]; 6. Randomized Controlled Trials as Topic; 7. Sepsis [epidemiology]; 8. Surgical Wound Infection [mortality, *prevention & control]; 9. *Transplant Recipients;
MESH terms:
Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients
1. Adamantane [adverse effects, analogs & derivatives, therapeutic use]; 2. Bias; 3. Cause of Death; 4. Diabetes Mellitus, Type 1 [blood, *drug therapy]; 5. Diabetes Mellitus, Type 2 [blood, *drug therapy]; 6. Dipeptidyl-Peptidase IV Inhibitors [adverse effects, *therapeutic use]; 7. Fasting [blood]; 8. Glycated Hemoglobin [metabolism]; 9. Graft Survival [drug effects]; 10. Hypoglycemia [chemically induced]; 11. Hypoglycemic Agents [adverse effects, *therapeutic use]; 12. Insulin [adverse effects, therapeutic use]; 13. Insulin Glargine [adverse effects, therapeutic use]; 14. Kidney Transplantation [*adverse effects]; 15. Nitriles [adverse effects, therapeutic use]; 16. Pioglitazone; 17. Postoperative Complications [*drug therapy, etiology]; 18. Pyrrolidines [adverse effects, therapeutic use]; 19. Randomized Controlled Trials as Topic; 20. Sitagliptin Phosphate [adverse effects, therapeutic use]; 21. Sodium-Glucose Transporter 2 Inhibitors [adverse effects, therapeutic use]; 22. Thiazolidinediones [adverse effects, therapeutic use]; 23. Transplant Recipients; 24. Vildagliptin;
MESH terms:
Early fortification of human milk versus late fortification to promote growth in preterm infants
1. Birth Weight; 2. Enterocolitis, Necrotizing [epidemiology]; 3. *Food, Fortified; 4. Head [growth & development]; 5. Infant, Premature [*growth & development]; 6. Infant, Very Low Birth Weight [*growth & development]; 7. *Milk, Human; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Topical treatment for facial burns
1. Administration, Topical; 2. Anti-Infective Agents [administration & dosage, *therapeutic use]; 3. Bias; 4. Burns [*therapy]; 5. Carboxymethylcellulose Sodium [administration & dosage, therapeutic use]; 6. Facial Injuries [*therapy]; 7. Randomized Controlled Trials as Topic; 8. *Skin, Artificial; 9. Wound Healing [drug effects];
MESH terms:
Education of family members to support weaning to solids and nutrition in later infancy in term‐born infants
1. Anemia, Iron-Deficiency [epidemiology]; 2. Bias; 3. Body Height; 4. Body Weight; 5. Child Development; 6. Developed Countries; 7. Developing Countries; 8. *Family; 9. Infant Death; 10. Infant Food; 11. Infant Nutrition Disorders [prevention & control]; 12. *Infant Nutritional Physiological Phenomena; 13. Prevalence; 14. Randomized Controlled Trials as Topic; 15. Term Birth; 16. *Weaning;
MESH terms:
Beta‐blockers for congestive heart failure in children
1. Adrenergic beta-Antagonists [*therapeutic use]; 2. Carbazoles [therapeutic use]; 3. Carvedilol; 4. Heart Failure [*drug therapy, mortality]; 5. Heart Transplantation [statistics & numerical data]; 6. Metoprolol [therapeutic use]; 7. Propanolamines [therapeutic use]; 8. Propranolol [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Stroke Volume;
MESH terms:
Workplace pedometer interventions for increasing physical activity
1. Actigraphy [*instrumentation]; 2. Bias; 3. Cardiovascular Diseases [etiology]; 4. Health Promotion [*methods]; 5. Motor Activity [*physiology]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Risk Factors; 9. Sedentary Behavior; 10. Walking [*physiology]; 11. *Workplace;
MESH terms:
Interventions for the management of obesity in people with bipolar disorder
1. Bipolar Disorder [*complications]; 2. Obesity [complications, *therapy];
MESH terms:
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis
1. Anti-Bacterial Agents [*administration & dosage]; 2. Antibodies, Monoclonal [therapeutic use]; 3. Bacterial Infections [*drug therapy, microbiology]; 4. beta Carotene [therapeutic use]; 5. Chemotherapy, Adjuvant; 6. Cystic Fibrosis [*complications]; 7. Disease Progression; 8. Garlic; 9. Immunoglobulin Fab Fragments [therapeutic use]; 10. Lung Diseases [*drug therapy, microbiology]; 11. Nitric Oxide [therapeutic use]; 12. Pseudomonas aeruginosa; 13. Pseudomonas Infections [drug therapy]; 14. Randomized Controlled Trials as Topic; 15. Vitamins [therapeutic use]; 16. Zinc [administration & dosage];
MESH terms:
Statins for asthma
1. Anti-Asthmatic Agents [*therapeutic use]; 2. Asthma [*drug therapy]; 3. Atorvastatin [*therapeutic use]; 4. Forced Expiratory Volume [drug effects]; 5. Hydroxymethylglutaryl-CoA Reductase Inhibitors [*therapeutic use]; 6. Peak Expiratory Flow Rate [drug effects];
MESH terms:
Head midline position for preventing the occurrence or extension of germinal matrix‐intraventricular haemorrhage in preterm infants
1. Beds; 2. Cerebral Intraventricular Hemorrhage [epidemiology, etiology, *prevention & control]; 3. Cerebrovascular Circulation [physiology]; 4. *Head; 5. Infant Mortality; 6. Infant, Premature; 7. Infant, Premature, Diseases [epidemiology, etiology, *prevention & control]; 8. Patient Positioning [*methods]; 9. Publication Bias; 10. Randomized Controlled Trials as Topic; 11. Retinopathy of Prematurity [epidemiology]; 12. Rotation; 13. *Supine Position;
MESH terms:
Psychological interventions for psychosis in adolescents
1. Bias; 2. Cognition [physiology]; 3. *Cognitive Remediation; 4. Combined Modality Therapy [methods]; 5. *Family Therapy; 6. Memory, Short-Term; 7. Patient Dropouts [statistics & numerical data]; 8. *Psychotherapy, Group; 9. Psychotic Disorders [*therapy]; 10. Schizophrenia [*therapy]; 11. Therapy, Computer-Assisted; 12. Treatment Outcome; 13. Video Games;
MESH terms:
Lamotrigine add‐on therapy for drug‐resistant generalised tonic‐clonic seizures
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Chemotherapy, Adjuvant [methods]; 3. Dizziness [chemically induced]; 4. Drug Eruptions [etiology]; 5. Drug Resistant Epilepsy [*drug therapy]; 6. Epilepsy, Tonic-Clonic [*drug therapy]; 7. Exanthema [chemically induced]; 8. Fatigue [chemically induced]; 9. Lamotrigine [adverse effects, *therapeutic use]; 10. Nausea [chemically induced]; 11. Patient Dropouts [statistics & numerical data]; 12. Randomized Controlled Trials as Topic; 13. Sleepiness;
MESH terms:
Use of reflective materials during phototherapy for newborn infants with unconjugated hyperbilirubinaemia
1. *Aluminum; 2. *Bedding and Linens; 3. Bias; 4. Bilirubin [blood]; 5. Hyperbilirubinemia, Neonatal [*therapy]; 6. Infant, Premature; 7. Jaundice, Neonatal [therapy]; 8. Lighting [instrumentation]; 9. Phototherapy [instrumentation, *methods]; 10. *Plastics; 11. Randomized Controlled Trials as Topic;
MESH terms:
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
1. Cause of Death; 2. Chelating Agents [adverse effects, *therapeutic use]; 3. Chelation Therapy [adverse effects, *methods]; 4. Chronic Disease; 5. Hyperkalemia [*drug therapy, etiology, mortality]; 6. Polymers [adverse effects, therapeutic use]; 7. Polystyrenes [adverse effects, therapeutic use]; 8. *Potassium; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Renal Insufficiency, Chronic [*complications]; 12. Silicates [adverse effects, therapeutic use];
MESH terms:
Ketogenic diets for drug‐resistant epilepsy
1. Age Factors; 2. Diet, Carbohydrate-Restricted [methods]; 3. Diet, High-Protein Low-Carbohydrate [methods]; 4. Diet, Ketogenic [adverse effects, *methods]; 5. Dietary Carbohydrates [*administration & dosage]; 6. Dietary Fats [*administration & dosage]; 7. Drug Resistant Epilepsy [*diet therapy]; 8. Intention to Treat Analysis; 9. Prospective Studies; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Retrospective Studies; 13. Sample Size;
MESH terms:
Cognitive‐behavioural therapy (CBT) interventions for young people aged 10 to 18 with harmful sexual behaviour
1. *Adaptation, Psychological; 2. Attitude; 3. Cognition Disorders [psychology]; 4. Cognitive Behavioral Therapy [*methods]; 5. Desensitization, Psychologic; 6. Fantasy; 7. Randomized Controlled Trials as Topic; 8. Rape [psychology]; 9. Recidivism; 10. Self Concept; 11. Sex Education; 12. Sex Offenses [*prevention & control, psychology]; 13. Social Skills;
MESH terms:
Pitavastatin for lowering lipids
1. Atorvastatin [administration & dosage]; 2. Cardiovascular Diseases [blood, prevention & control]; 3. Cholesterol, HDL [blood]; 4. Cholesterol, LDL [blood]; 5. Controlled Before-After Studies; 6. Drug Administration Schedule; 7. Fluvastatin [administration & dosage]; 8. Hydroxymethylglutaryl-CoA Reductase Inhibitors [*administration & dosage]; 9. Lipids [*blood]; 10. Pyridines [administration & dosage]; 11. Quinolines [*administration & dosage]; 12. Randomized Controlled Trials as Topic; 13. Rosuvastatin Calcium [administration & dosage]; 14. Sex Factors; 15. Triglycerides [blood];
MESH terms:
Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children
1. Anticoagulants [administration & dosage, adverse effects, *therapeutic use]; 2. Catheter Obstruction [statistics & numerical data]; 3. Catheterization, Central Venous [*adverse effects]; 4. Hemorrhage [chemically induced]; 5. Heparin [administration & dosage]; 6. Heparin, Low-Molecular-Weight [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Thrombosis [etiology, *prevention & control];
MESH terms:
Ventriculo‐peritoneal shunting devices for hydrocephalus
1. Equipment Design; 2. Hydrocephalus [complications, mortality, *surgery]; 3. Microcomputers; 4. Randomized Controlled Trials as Topic; 5. Treatment Failure; 6. Uncertainty; 7. Ventriculoperitoneal Shunt [adverse effects, *instrumentation, mortality];
MESH terms:
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis
1. Anti-Bacterial Agents [*therapeutic use]; 2. Biofilms [*drug effects, growth & development]; 3. Cystic Fibrosis [*complications]; 4. Microbial Sensitivity Tests [methods]; 5. Pseudomonas aeruginosa [*drug effects, physiology]; 6. Pseudomonas Infections [complications, *drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Tract Infections [*drug therapy, microbiology]; 9. Sputum [microbiology];
MESH terms:
Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis
1. Anti-Bacterial Agents [*therapeutic use]; 2. Cystic Fibrosis [*microbiology]; 3. Drug Therapy, Combination [methods]; 4. Lung Diseases [*drug therapy, microbiology]; 5. Mycobacterium abscessus; 6. Mycobacterium avium Complex; 7. Mycobacterium Infections, Nontuberculous [*drug therapy]; 8. Nontuberculous Mycobacteria;
MESH terms:
Vitamin K supplementation for cystic fibrosis
1. Biomarkers [blood]; 2. Blood Coagulation [drug effects]; 3. Bone Density; 4. Cystic Fibrosis [*blood, complications]; 5. Dietary Supplements; 6. Fractures, Bone [prevention & control]; 7. Osteocalcin [blood]; 8. Osteogenesis [*drug effects]; 9. Protein Precursors [blood]; 10. Prothrombin; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Vitamin K [*administration & dosage, blood]; 14. Vitamin K Deficiency [complications, *drug therapy]; 15. Vitamins [*administration & dosage];
MESH terms:
Multi‐nutrient fortification of human milk for preterm infants
1. *Food, Fortified; 2. *Infant Nutritional Physiological Phenomena; 3. Infant, Premature [*growth & development]; 4. Milk, Human [*chemistry]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Effects of total fat intake on body fatness in adults
1. *Adipose Tissue; 2. *Adiposity; 3. Blood Pressure; 4. Body Mass Index; 5. Body Weight; 6. Cholesterol [blood]; 7. Cholesterol, HDL [blood]; 8. Cholesterol, LDL [blood]; 9. Diet, Fat-Restricted; 10. Diet, High-Protein; 11. Dietary Fats [*administration & dosage]; 12. *Energy Intake; 13. Quality of Life; 14. Randomized Controlled Trials as Topic; 15. Triglycerides [blood]; 16. Waist Circumference;
MESH terms:
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non‐hospitalised term infants
1. Administration, Oral; 2. Body Weight [drug effects]; 3. Breast Feeding; 4. Domperidone [administration & dosage, adverse effects]; 5. Galactogogues [*administration & dosage, adverse effects]; 6. Lactation [*drug effects]; 7. Metoclopramide [administration & dosage, adverse effects]; 8. *Milk, Human [drug effects]; 9. Mothers; 10. Phytotherapy [adverse effects, *methods]; 11. Plant Extracts [*administration & dosage, adverse effects]; 12. Randomized Controlled Trials as Topic; 13. Sulpiride [administration & dosage, adverse effects]; 14. Thyrotropin-Releasing Hormone [administration & dosage, adverse effects];
MESH terms:
Interventions for congenital talipes equinovarus (clubfoot)
1. Botulinum Toxins, Type A [therapeutic use]; 2. Casts, Surgical; 3. Clubfoot [*therapy]; 4. Decompression, Surgical [methods]; 5. Ligaments, Articular [surgery]; 6. Motion Therapy, Continuous Passive [methods]; 7. Neuromuscular Agents [therapeutic use]; 8. Orthopedic Procedures [methods]; 9. Randomized Controlled Trials as Topic; 10. Recurrence; 11. Treatment Outcome;
MESH terms:
Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis
1. Anti-Bacterial Agents [*therapeutic use]; 2. Chronic Disease; 3. Cystic Fibrosis [*microbiology]; 4. Disease Progression; 5. Drug Therapy, Combination; 6. Microbial Sensitivity Tests; 7. *Pseudomonas aeruginosa [drug effects]; 8. Pseudomonas Infections [*drug therapy]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Artificial corneas versus donor corneas for repeat corneal transplants
1. *Artificial Organs; 2. *Cornea; 3. *Corneal Transplantation; 4. Reoperation;
MESH terms:
Alarm interventions for nocturnal enuresis in children
1. Absorbent Pads; 2. Case-Control Studies; 3. *Clinical Alarms; 4. Combined Modality Therapy [methods]; 5. Deamino Arginine Vasopressin [therapeutic use]; 6. Nephrology [methods]; 7. Nocturnal Enuresis [drug therapy, *prevention & control]; 8. Placebos [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Renal Agents [therapeutic use]; 11. Treatment Outcome;
MESH terms:
Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne
1. Acne Vulgaris [*drug therapy]; 2. Adapalene [adverse effects, therapeutic use]; 3. Anti-Bacterial Agents [therapeutic use]; 4. Benzoyl Peroxide [therapeutic use]; 5. Bias; 6. Clindamycin [adverse effects, therapeutic use]; 7. Dermatologic Agents [adverse effects, *therapeutic use]; 8. Dicarboxylic Acids [adverse effects, therapeutic use]; 9. Erythromycin [adverse effects, therapeutic use]; 10. Glycolates [therapeutic use]; 11. Keratolytic Agents [therapeutic use]; 12. Mandelic Acids [therapeutic use]; 13. Niacinamide [adverse effects, therapeutic use]; 14. Patient Dropouts [statistics & numerical data]; 15. Pyruvic Acid [adverse effects, therapeutic use]; 16. Quality of Life; 17. Salicylic Acid [therapeutic use]; 18. Sulfur [therapeutic use]; 19. Tretinoin [therapeutic use]; 20. Zinc [therapeutic use];
MESH terms:
Corticosteroids as standalone or add‐on treatment for sore throat
1. Adrenal Cortex Hormones [*administration & dosage]; 2. Anti-Bacterial Agents [*administration & dosage]; 3. Drug Therapy, Combination [methods]; 4. Pharyngitis [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Time Factors; 7. Tonsillitis [drug therapy]; 8. Treatment Outcome;
MESH terms:
Inhaled mannitol for cystic fibrosis
1. Administration, Inhalation; 2. Cystic Fibrosis [*drug therapy, physiopathology]; 3. Deoxyribonuclease I [*administration & dosage]; 4. Forced Expiratory Volume; 5. Mannitol [*administration & dosage, adverse effects]; 6. Mucociliary Clearance; 7. Powders; 8. Randomized Controlled Trials as Topic; 9. Recombinant Proteins [administration & dosage]; 10. Respiratory Function Tests; 11. Vital Capacity;
MESH terms:
Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long‐term central venous catheters in infants and children
1. *Catheter Obstruction [statistics & numerical data]; 2. Catheter-Related Infections [epidemiology, prevention & control]; 3. *Central Venous Catheters [adverse effects, statistics & numerical data]; 4. Fibrinolytic Agents [*administration & dosage]; 5. Heparin [*administration & dosage]; 6. Randomized Controlled Trials as Topic; 7. Sodium Chloride [*administration & dosage];